netupitant

Known as: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide, 2-[3,5-bis(Trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide 
A selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
0102020062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Safe, effective and convenient antiemetic regimens that preserve benefit over repeated cycles are needed for optimal… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
BACKGROUND Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis… (More)
  • figure 1
  • figure 3
  • table 1
  • table 3
  • table 2
Is this relevant?
2014
2014
BACKGROUND NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK1) receptor… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2014
2014
Netupitant is a new, selective NK1 receptor antagonist under development for the prevention of chemotherapy-induced nausea and… (More)
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Current therapy for chemotherapy-induced nausea and vomiting includes the use of both 5-HT3 and NK1 receptor antagonists. Acute… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
Chemotherapy-induced nausea and vomiting is ranked among the worst side effects of chemotherapy. NEPA is an oral fixed-dose… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2013
2013
Netupitant is a new highly selective neurokinin-1 receptor antagonist being studied for the prevention of nausea and vomiting in… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2013
2012
2012
The novel NK(1) receptor ligand Netupitant has been characterized in vitro and in vivo. In calcium mobilization studies CHO cells… (More)
Is this relevant?
2012
2012
Netupitant is a potent and selective NK(1) receptor antagonist under development in combination with a fixed dose of palonosetron… (More)
Is this relevant?